[go: up one dir, main page]

NO974596L - Transplantasjon av genetisk modifiserte celler som har lave nivåer av klasse I MCH proteiner på celleoverflaten - Google Patents

Transplantasjon av genetisk modifiserte celler som har lave nivåer av klasse I MCH proteiner på celleoverflaten

Info

Publication number
NO974596L
NO974596L NO974596A NO974596A NO974596L NO 974596 L NO974596 L NO 974596L NO 974596 A NO974596 A NO 974596A NO 974596 A NO974596 A NO 974596A NO 974596 L NO974596 L NO 974596L
Authority
NO
Norway
Prior art keywords
cells
genetically modified
transplantation
class
proteins
Prior art date
Application number
NO974596A
Other languages
English (en)
Other versions
NO974596D0 (no
Inventor
Gillis R Otten
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of NO974596D0 publication Critical patent/NO974596D0/no
Publication of NO974596L publication Critical patent/NO974596L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Pattedyrceller modifiseres genetisk ved innføringen av gener som koder for virus-avledede MHC ned-regulerende proteiner. Egnede celler for transplantasjon tas fra en donor og transfekteres med en ekspresjonsvektor som koder for ett eller flere virus-avledede MHC ned-regulerende proteiner. De genetisk modifiserte donorcellene ekspanderes ex vivo, om relevant, og transplanteres til en mottagende pattedyrvert. De nedsatte nivåer av klasse l MHC-protein lar de transplanterte cellene overleve under betingelser hvor de genetisk umodifiserte cellene ellers ville være gjenstand for angrep av mottagerens immunsystem. Donorcellene kan modifiseres ytterligere for å målsøke celler eller for å forbedre effektorfunksjonen av dojiorcellene i pattedyrverten.
NO974596A 1995-04-04 1997-10-03 Transplantasjon av genetisk modifiserte celler som har lave nivåer av klasse I MCH proteiner på celleoverflaten NO974596L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41610695A 1995-04-04 1995-04-04
PCT/US1996/004648 WO1996031241A1 (en) 1995-04-04 1996-04-03 Transplantation of genetically modified cells having low levels of class i mhc proteins on the cell surface

Publications (2)

Publication Number Publication Date
NO974596D0 NO974596D0 (no) 1997-10-03
NO974596L true NO974596L (no) 1997-12-03

Family

ID=23648556

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974596A NO974596L (no) 1995-04-04 1997-10-03 Transplantasjon av genetisk modifiserte celler som har lave nivåer av klasse I MCH proteiner på celleoverflaten

Country Status (7)

Country Link
EP (1) EP0820311A4 (no)
JP (1) JPH11503024A (no)
KR (1) KR19980703665A (no)
AU (1) AU712415B2 (no)
CA (1) CA2217297A1 (no)
NO (1) NO974596L (no)
WO (1) WO1996031241A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047914A2 (de) * 1997-04-18 1998-10-29 Roche Diagnostics Gmbh Us6 gen aus dem humanen cytomegalovirus (hcmv)
EP1045920A1 (en) * 1998-01-14 2000-10-25 Human Gene Therapy Research Institute Nucleotide expression systems with reduced immunogenicity for use in gene therapy
EP1020520A1 (en) * 1999-01-15 2000-07-19 Introgene B.V. Prevention of immune related removal of cells from the mammalian body, mutant PML molecules useful therefor
CA2793959C (en) * 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2798136C (en) 2010-05-14 2019-06-04 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
US20120020885A1 (en) * 2010-07-26 2012-01-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware MHC-Less cells
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
JP6487026B2 (ja) 2014-07-16 2019-03-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 外来抗原を含むヒトサイトメガロウイルス
JP6816031B2 (ja) 2015-02-10 2021-01-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
CA3005136A1 (en) 2015-11-20 2017-05-26 Oregon Health & Science University Cmv vectors comprising microrna recognition elements
TN2019000124A1 (en) 2016-10-18 2020-10-05 Univ Oregon Health & Science Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules
KR20190141206A (ko) * 2017-04-19 2019-12-23 알로젠 테라퓨틱스 인코포레이티드 개선된 t 세포 조성물 및 방법
WO2019167973A1 (en) * 2018-03-01 2019-09-06 Kyoto University Cell cycle progression inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0517895B1 (en) * 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells

Also Published As

Publication number Publication date
CA2217297A1 (en) 1996-10-10
NO974596D0 (no) 1997-10-03
WO1996031241A1 (en) 1996-10-10
EP0820311A4 (en) 2002-09-25
AU5533896A (en) 1996-10-23
EP0820311A1 (en) 1998-01-28
KR19980703665A (ko) 1998-12-05
JPH11503024A (ja) 1999-03-23
AU712415B2 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
NO974596L (no) Transplantasjon av genetisk modifiserte celler som har lave nivåer av klasse I MCH proteiner på celleoverflaten
Lake et al. Was the nucleus the first endosymbiont?
Tooze et al. Condensation-sorting events in the rough endoplasmic reticulum of exocrine pancreatic cells.
CA2193094A1 (en) The cytoplasmic inhibition of gene expression
DE3471688D1 (en) Dna vectors and their use in recombinant dna technology
HUP0101136A2 (hu) Fehérjeexpresszió baculovírus-vektort alkalmazó expressziós rendszerben
RU94030817A (ru) Днк, белок,вектор, клетка, способ получения продукта
KR910015309A (ko) 종양괴사인자(tnf) 억제제 및 그 제조방법
RU2007110808A (ru) Способы культивирования цирковирусов
KR960700344A (ko) 유전자 전환성 식물내 재조합 전령 rna의 비루스성 증식방법(viral amplification of recombinant messenger rna in transgenic plants)
DE68928445D1 (de) Potyvirus-hüllproteingene und damit transformierte pflanzen
KR930701610A (ko) 미생물의 세포, 조직 또는 숙주 지향성을 변화시키는 방법, 이 방법으로 수득된 재조합 미생물, 및 의학 및 수의학분야에서 이들을 사용하는 방법
Morgenstern Coated membranes in blood platelets
EA199900507A1 (ru) Способы профилактики отторжения трансплантата при трансплантации и продуцирования универсальной клетки-хозяина для генной терапии
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
KR950704477A (ko) 형질 전환된 내피 세포(transformed endothelial cells)
KR880701285A (ko) Aids 비루스의 f단백질을 함유하는 백신
KR960029343A (ko) 아르기닌 존재시에 원핵 미생물로부터 주변세포질형 단백질의 추출방법
NO951315L (no) Ökt produksjon av utsondrede proteiner fra rekombinante eukaryote-celler
FUJISHIMA et al. Quantitative changes in periplasmic proteins of the macronucleus‐specific bacterium Holospora obtusa in the infection process of the ciliate Paramecium caudatum
Cardemil et al. Expression of cell wall proteins in seeds and during early seedling growth of Araucaria araucana is a response to wound stress and is developmentally regulated
KR970010968A (ko) 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
KR880007728A (ko) 비루스 벡터 및 재조합 dna
KR880003008A (ko) 우역 바이러스의 항원 단백질을 코드화 하는 dna
RU2001104431A (ru) Способ получения белков в трансформированных дрожжевых клетках

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application